Dose-dependent anti-inflammatory effect of inhaled mometasone furoate/formoterol in subjects with asthma

Respiratory Medicine

Volumn 107, Issue 5, 2013, Pages 656-664

  Nolte, Hendrik ^a   Pavord, Ian ^b   Backer, Vibeke ^c   Spector, Sheldon ^d   Shekar, Tulin ^a   Gates, Davis ^a   Nair, Parameswaran ^e   Hargreave, Frederick ^e  

^a MERCK RESEARCH LABORATORIES   (United States)

^b GLENFIELD HOSPITAL   (United Kingdom)

^c BISPEBJERG HOSPITAL   (Denmark)

^d California Allergy and Asthma Medical Group   (United States)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

Asthma; Exhaled nitric oxide; Mometasone furoate formoterol; Phenotype; Sputum eosinophil

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; MOMETASONE FUROATE; NITRIC OXIDE; PLACEBO; SALBUTAMOL; TERBUTALINE;

ADULT; ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG TOLERANCE; DRY POWDER; EOSINOPHIL COUNT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OROPHARYNX PAIN; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; SPUTUM ANALYSIS;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; ASTHMA; BREATH TESTS; BRONCHODILATOR AGENTS; CIRCADIAN RHYTHM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; EOSINOPHILS; ETHANOLAMINES; FEMALE; GLUCOCORTICOIDS; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NITRIC OXIDE; PEAK EXPIRATORY FLOW RATE; PREGNADIENEDIOLS; SPUTUM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84876035227     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2013.02.010     Document Type: Article

References (26)

1. Global Initiative for Asthma Global strategy for asthma management and prevention 2008 July 30, 2009 Available from: http://www.ginasthma.com/ Guidelineitem.aspl1=2&l2=1&intId=1561 [cited 20.01.10]
2. National Asthma Education and Prevention Program Expert panel report 3: guidelines for the diagnosis and management of asthma. Full report 2007 Available from: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm [cited 14.12.10]
3. A. Sindi, D.C. Todd, and P. Nair Antiinflammatory effects of long-acting beta2-agonists in patients with asthma: a systematic review and metaanalysis Chest 136 1 2009 Jul 145 154
4. A.D. Smith, J.O. Cowan, K.P. Brassett, G.P. Herbison, and D.R. Taylor Use of exhaled nitric oxide measurements to guide treatment in chronic asthma N Engl J Med 352 21 2005 May 26 2163 2173
5. E. Bacci, S. Cianchetti, M. Bartoli, F.L. Dente, A. Di Franco, and B. Vagaggini Low sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients Chest 129 3 2006 Mar 565 572
6. M.M. Kelly, R. Leigh, L. Jayaram, C.H. Goldsmith, K. Parameswaran, and F.E. Hargreave Eosinophilic bronchitis in asthma: a model for establishing dose-response and relative potency of inhaled corticosteroids J Allergy Clin Immunol 117 5 2006 May 989 994
7. I.D. Pavord, C.E. Brightling, G. Woltmann, and A.J. Wardlaw Non-eosinophilic corticosteroid unresponsive asthma Lancet 353 9171 1999 Jun 26 2213 2214
8. K. Lonnkvist, C. Hellman, J. Lundahl, G. Hallden, and G. Hedlin Eosinophil markers in blood, serum, and urine for monitoring the clinical course in childhood asthma: impact of budesonide treatment and withdrawal J Allergy Clin Immunol 107 5 2001 May 812 817
9. R.J. Meijer, D.S. Postma, H.F. Kauffman, L.R. Arends, G.H. Koeter, and H.A. Kerstjens Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma Clin Exp Allergy 32 7 2002 Jul 1096 1103
10. L. Jayaram, M.M. Pizzichini, R.J. Cook, L.P. Boulet, C. Lemiere, and E. Pizzichini Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations Eur Respir J 27 3 2006 Mar 483 494
11. R.H. Green, C.E. Brightling, S. McKenna, B. Hargadon, D. Parker, and P. Bradding Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial Lancet 360 9347 2002 Nov 30 1715 1721
12. S.J. Szefler, R.J. Martin, T.S. King, H.A. Boushey, R.M. Cherniack, and V.M. Chinchilli Significant variability in response to inhaled corticosteroids for persistent asthma J Allergy Clin Immunol 109 3 2002 Mar 410 418
13. A.M. Wilson, and B.J. Lipworth Dose-response evaluation of the therapeutic index for inhaled budesonide in patients with mild-to-moderate asthma Am J Med 108 4 2000 Mar 269 275
14. American Thoracic Society W ATS Workshop proceedings: exhaled nitric oxide and nitric oxide oxidative metabolism in exhaled breath condensate: executive summary Am J Respir Crit Care Med 173 7 2006 Apr 1 811 813
15. P.L. Paggiaro, P. Chanez, O. Holz, P.W. Ind, R. Djukanovic, and P. Maestrelli Sputum induction Eur Respir J Suppl 37 2002 Sep 3s 8s
16. P. Nair, and F.E. Hargreave Measuring bronchitis in airway diseases: clinical implementation and application: airway hyperresponsiveness in asthma: its measurement and clinical significance Chest 138 Suppl. 2 2010 Aug 38S 43S
17. M.R. Miller, J. Hankinson, V. Brusasco, F. Burgos, R. Casaburi, and A. Coates Standardisation of spirometry Eur Respir J 26 2 2005 Aug 319 338
18. J.D. Brannan, S.D. Anderson, C.P. Perry, R. Freed-Martens, A.R. Lassig, and B. Charlton The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline Respir Res 6 2005 144
19. S.D. Anderson, J. Brannan, J. Spring, N. Spalding, L.T. Rodwell, and K. Chan A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol Am J Respir Crit Care Med 156 3 Pt 1 1997 Sep 758 765
20. H.K. Reddel, D.R. Taylor, E.D. Bateman, L.P. Boulet, H.A. Boushey, and W.W. Busse An official American thoracic society/European respiratory society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice Am J Respir Crit Care Med 180 1 2009 Jul 1 59 99
21. K. Parameswaran, R. Leigh, P.M. O'Byrne, M.M. Kelly, C.H. Goldsmith, and F.E. Hargreave Clinical models to compare the safety and efficacy of inhaled corticosteroids in patients with asthma Can Respir J 10 1 2003 Jan-Feb 27 34
22. S.L. Jones, P. Herbison, J.O. Cowan, E.M. Flannery, R.J. Hancox, and C.R. McLachlan Exhaled NO and assessment of anti-inflammatory effects of inhaled steroid: dose-response relationship Eur Respir J 20 3 2002 Sep 601 608
23. M.D. Inman, R.M. Watson, T. Rerecich, G.M. Gauvreau, B.N. Lutsky, and P. Stryszak Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge Am J Respir Crit Care Med 164 4 2001 Aug 15 569 574
24. H. Meurs, R. Gosens, and J. Zaagsma Airway hyperresponsiveness in asthma: lessons from in vitro model systems and animal models Eur Respir J 32 2 2008 Aug 487 502
25. D.E. Geller Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler Respir Care 50 10 2005 Oct 1313 1321 [discussion 21-2]
26. R.A. Dweik, P.B. Boggs, S.C. Erzurum, C.G. Irvin, M.W. Leigh, and J.O. Lundberg An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications Am J Respir Crit Care Med 184 5 2011 Sep 1 602 615